Description

Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor agonist. Bamadutide (SAR425899) improves postprandial glucose control by significantly enhancing β-cell function and slowing glucose absorption rate in vivo. Bamadutide (SAR425899)can be used for type 2 diabetes research[1].—Metabolism-sugar/lipid metabolism–C200H313N51O63—-[1]Olof Eriksson, et al.Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.J Nucl Med.2021 Jun 1;62(6):833-838.–1596343-09-7–4439.93—-OC[C@@H](C(N)=O)NC([C@H]1N(C([C@H]2N(C([C@H]3N(C([C@H](C)NC(CNC([C@H](CO)NC([C@H](CO)NC([C@H]4N(C(CNC(CNC([C@H](C)NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](CC5=CNC6=C5C=CC=C6)NC([C@H](CCC(O)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC7=CC=CC=C7)NC([C@H](CC(O)=O)NC([C@H](CCC(N)=O)NC([C@H](C)NC([C@H](C)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CCC(O)=O)NC([C@H](CCCCNC(CC[C@@H](C(O)=O)NC(CCCCCCCCCCCCCCC)=O)=O)NC([C@H](CCC(N)=O)NC([C@H](CCCCN)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@H](O)C)NC([C@H](CC8=CC=CC=C8)NC([C@H]([C@H](O)C)NC(CNC([C@H](CCC(N)=O)NC([C@@H](CO)NC([C@H](CC9=CNC=N9)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC4)=O)=O)=O)=O)=O)CCC3)=O)CCC2)=O)CCC1)=O–Metabolic Disease–10 mM in DMSO–GCGR;GLP Receptor—-GPCR/G Protein–Peptides